About

Chief Scientific Advisor

Professor Roger Kornberg

Roger D. Kornberg, Nobel Laureate in Chemistry (2006), is a celebrated figure in the scientific community, best known for his groundbreaking work on the molecular basis of eukaryotic transcription. Born in St. Louis, Missouri, into a family deeply rooted in biochemistry—his father, Arthur Kornberg, also won a Nobel Prize—Roger has continued this legacy with his own significant contributions to the field.

Kornberg’s journey in the sciences began with his education at Harvard University, where he earned his bachelor’s degree in chemistry in 1967. He furthered his studies at Stanford University, obtaining a Ph.D. in Physical Chemistry in 1972. His postdoctoral research took him to the Laboratory of Molecular Biology in Cambridge, England, and later to Harvard Medical School as an Assistant Professor of Biological Chemistry. In 1978, he joined Stanford Medical School as a Professor of Structural Biology, a position he still holds today.

His research has been pivotal in understanding the process of DNA transcription. He identified the role of RNA polymerase II and other proteins in this process and used X-ray crystallography to create three-dimensional images of these protein clusters. His discoveries extend to the “flip-flop” and lateral diffusion of phospholipids in bilayer membranes and the nucleosome’s role as a basic protein complex packaging chromosomal DNA in eukaryotic cells. Kornberg’s work with the nucleosome illuminated its function as a general gene repressor and its regulatory role in transcription.

Moreover, Kornberg’s lab at Stanford succeeded in developing a transcription system from baker’s yeast, which helped isolate the proteins required for the transcription process. His discovery of the Mediator complex was a milestone in understanding the transcription process in eukaryotic organisms.

Our Team

CEO

Chief Innovation Officer

Carmit Lev

HR & Operations Manager

Liraz Harel, Ph.D.

Associate Director for R&D

Avi Dayan, Ph.D.

Senior Scientist

Hamutal Ben Dov, Ph.D.

Senior Scientist

Ylena Poliansky, DVM

Attending Veterinarian

Rawan Saeed, M.Sc.

Research Assistant

Shira Bezaleli

Bookeeper & Salary Administrator

Jonathan Zonszain Ph.D.

Senior Researcher

Dor Lavie M.Sc.

Researcher

Harel Yaakovi

R&D Operations Coordinator

Nuphar Shidlovsky M.Sc.

Researcher

Board of Directors

Prof. Alon Dumanis, Chairman of the Board

Dr. Alon Dumanis, is the Chief Executive Officer of Dumanis Investments Ltd and its affiliates. He is currently a chairman of Aposense (TASE-APOS), a member of the board of directors of Nova Measuring Instruments (NASDAQ-NVMI) and Rada Electronic Industries (NASDAQ-RADA), Managing Partner of Augmentum Ltd., and CEO of ACS Air-Cyber Solutions Ltd. Dr. Dumanis was for 15 years (till 2015) the Chief Executive Officer of Docor International Management Ltd. and the General Manager of Crecor B.V. and Docor International B.V., Dutch investment companies, subsidiaries of The Van-Leer Group Foundation.

Mr. Jacob Gottenstein, Co-founder

Mr. Gottenstein is Chairman of the Board of Israel Petrochemical Enterprises and is a part of the controlling shareholders and a director in Israel’s Oil refineries limited (TASE: ORL). Mr. Gottenstein has a vast activity in different ventures in both industry, biotech and tech.

Dr. Morry Blumenfeld

Dr. Blumenfeld is a partner in Ziegler-Meditech Equity Partners and is a former medical imaging technology leader in GE Medical Systems, where for many years he led the technology development for GE’s CT and MRI business sectors.

Dr. Shlomo Segev

Dr. Shlomo Segev is the head of the Institute For Medical Screening at the Chaim Sheba Medical Center Tel-Hashomer. He served as the personal physician of three Israeli prime ministers, Yitzhak Rabin, Ariel Sharon and Ehud Olmert, as well as the personal physician of former President of Israel Shimon Peres. Dr. Shlomo Segev serves as a board member and medical advisor for various medical product companies and startups.

Mr. Amos Bar Shalev

Mr. Bar Shalev managed several VC Funds, and is on the board of Protalix, Twine, Ripples, PetNovations and others. He received his BSc from the Technion and MBA from Tel Aviv University.

Ms. Yael Vinokursky

Ms. Yael Vinokursky is the CFO of ID Federman Holdings Ltd and of the Modgal Group companies. She holds a BA in Economics and an MBA in Business Management, both from TA university.

Prof. Yehuda Adler, M.D, M.H.A

Director, Development of Medical Resources; Director, Talpiot Medical Leadership Program; Chairman, Sheba Internship Committee, The Chaim Sheba Medical Center, Tel Hashomer, Israel.

Mr. Eli Mandelberg

Mr. Mandelberg was an Executive VP for business development of Solel Solar Systems and Heliofocus. He is an independent consultant and Director at Tamuz Energy. Holds a BSc. In Mechanical engineering followed by business management studies – TA University.

Board of Directors

Prof. Alon Dumanis, Chairman of the Board

Prof. Alon Dumanis, is the Chief Executive Officer of Dumanis Investments Ltd and its affiliates. He is currently a chairman of Aposense (TASE-APOS), a member of the board of directors of Nova Measuring Instruments (NASDAQ-NVMI) and Rada Electronic Industries (NASDAQ-RADA), Managing Partner of Augmentum Ltd., and CEO of ACS Air-Cyber Solutions Ltd. Dr. Dumanis was for 15 years (till 2015) the Chief Executive Officer of Docor International Management Ltd. and the General Manager of Crecor B.V. and Docor International B.V., Dutch investment companies, subsidiaries of The Van-Leer Group Foundation.

Mr. Yaacov Gottenstein

Mr. Gottenstein is Chairman of the Board of Israel Petrochemical Enterprises (TASE: PTCH), and a co-founder of Aposense.

Dr. Morry Blumenfeld

Dr. Blumenfeld is a partner in Ziegler-Meditech Equity Partners, and is a former medical imaging technology leader in GE Medical Systems, where for many years he led the technology development for GE’s CT and MRI business sectors.

Dr. Joseph Dubrovsky

Dr. Blumenfeld is a partner in Ziegler-Meditech Equity Partners, and is a former medical imaging technology leader in GE Medical Systems, where for many years he led the technology development for GE’s CT and MRI business sectors.

Ms. Yael Vinokursky

Ms. Yael Vinokursky is the CFO of ID Federman Holdings Ltd and of the Modgal Group companies. She hold a BA in Economics and an MBA in Business Management, both from TA university

Mr. Amos Bar Shalev

Mr. Bar Shalev managed several VC Funds, and is on the board of Protalix, Twine, Ripples, PetNovations and others. He received his BSc from the Technion and MBA from Tel Aviv University.

Prof. Yehuda Adler, M.D, M.H.A​

Director, Development of Medical Resources; Director, Talpiot Medical Leadership Program; Chairman, Sheba Internship Committee, The Chaim Sheba Medical Center, Tel Hashomer, Israel.

Mr. Eli Mandelberg

Mr. Mandelberg was an Executive VP for business development of Solel Solar Systems and Heliofocus. He is an Independent consultant and Director at Tamuz Energy. Holds a BSc. In Mechanical engineering followed by business management studies – TA University.

Ms. Michal Noy

Ms. Noy is an Advocate, holds an LLB from the Hebrew University of Jerusalem. , She is an Investment Banker of Israeli companies, in the fields of industry, finance and technology. She serves as a Board Member of several public companies.

Mr. Amos Mar-Haim

Mr. Amos Mar-Haim served as Director General at Israeli Ministry of Trade and Industry. Mr. Mar-Haim’s business career began in 1979 as a Director General of AML Corp. Ltd. and then of Clal Industries Ltd. From 1989 to 1994, Mr. Mar-Haim served as a Senior Deputy Mayor of Jerusalem and later as the Mayor of the city of Bnei-Brak.

Yuval Gottenstein

Yuval possesses a broad range of knowledge and experience in the financial and pharma markets, leading projects from early R&D into commercialization. Throughout the years Yuval has raised numerous investment rounds, structured complex transactions and performed out licensing deals with substantial accumulated monetary value. Yuval holds a Master’s degree in Business Administration from Tel Aviv University.

Guy Kornberg Ph.D.

Dr. Kornberg has a BA in Economics from Stanford University, and a PhD in Biophysics from the Stanford University School of Medicine.  With the completion of his PhD in 2014, Guy returned to Israel and was selected for service in the Office of the Prime Minister.  Guy worked in the Prime Minister’s Office for eight years, receiving a number of commendations and rising through the ranks to senior management.  In addition to his academic background, Guy has gained hands on experience in a variety of technological and operational fields, as well as experience managing multidisciplinary teams responsible for projects with strategic importance.

Hagit Grimberg, Ph.D.

Dr. Grimberg has been with Aposense for the past 14 years. She has a strong background in innovation, research and novel product development, with experience driving development from the drawing board and into the clinic. Dr. Grimberg is responsible for leading Aposense’s therapeutic R&D projects through all developmental stages. Prior to her current position, Dr. Grimberg served as Project Manager at Aposense. Dr. Grimberg obtained an M.Sc in Biochemistry from Ben Gurion University and a Ph.D in Physiology & Pharmacology from Tel Aviv University. Dr. Grimberg has published several articles in leading journals and holds numerous patents.

Joel Van Gelder, Ph.D.

Dr. Van Gelder has over 25 years of experience in the biopharmaceutical industry in research and development programs of small molecules and biologicals for various indications.  Dr. Van Gelder served as Principal Scientist at FutuRx, as Scientific Manager at Tarom Innovative Technologies, as Chief Scientist of InSight Biopharmaceuticals, as Associate Director of Chemistry at Aposense and Head of Chemical R&D at Gamida Cell. Dr. Van Gelder holds a Ph.D. in Pharmaceutical Sciences from the School of Pharmacology at the Hebrew University, Jerusalem.

Etty Genis Barak

Ms. Genis began her career at Ernst & Young, where she was a manager and spent 4 productive years.  While at Ernst & Young Ms. Genis was responsible for both privately held and publicy listed clients (mainly NASDAQ) in the technology and communications sectors.  Prior to joining Aposense, Ms. Genis was a controller at Radview Software Ltd.  Ms. Genis has worked at Aposense since 2008 and took part in Aposense’s successful IPO on the TASE in 2010. Ms. Genis is a Certified Public Accountant (CPA) and holds a BA in Accounting from the College of Management at Tel Aviv University.